Literature DB >> 7672703

Absence of significant germ line p53 mutations in ovarian cancer patients.

R E Buller1, J S Skilling, S Kaliszewski, T Niemann, B Anderson.   

Abstract

Germ line mutations of the p53 gene have been described in the Li-Fraumeni Cancer Family Syndrome and occur in patients with multifocal gliomas, particularly those with a history of a metachronous cancer or a family history of cancer. p53 dysfunction is often associated with ovarian cancer. Patients with ovarian carcinoma frequently develop synchronous or metachronous cancers and may have a family history of this or related cancers. Thus, we hypothesized that germ line p53 mutations might be associated with a significant proportion of ovarian cancers. Germ line DNA isolated from peripheral leukocytes of 73 patients with ovarian carcinoma was screened for p53 sequence abnormalities utilizing single-strand conformation polymorphism analysis and direct PCR sequencing techniques. As many as 40% of this cohort of ovarian cancer patients from 67 families may represent familial phenotypes. Synchronous and metachronous cancers occurred in 19% of the cohort. Only two intron-based polymorphisms were found. Neither has been previously reported. One of these, in intron 6, occurred in three unrelated patients all of whom had a history of metachronous breast cancer. A polymorphism in intron 10 occurred in a patient with synchronous endometrial cancer. No classic germ line mutations of p53 were found.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7672703     DOI: 10.1006/gyno.1995.1244

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Forth nightly review: hereditary ovarian carcinoma.

Authors:  L Kasprzak; W D Foulkes; A N Shelling
Journal:  BMJ       Date:  1999-03-20

2.  Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15.

Authors:  José Luis Soto Martínez; Carmen M Cabrera Morales; Sabio Serrano Ortega; Miguel Angel López-Nevot
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

3.  Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B.

Authors:  José Luis Soto; Carmen M Cabrera; Salvio Serrano; Miguel Angel López-Nevot
Journal:  BMC Cancer       Date:  2005-04-08       Impact factor: 4.430

4.  The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia.

Authors:  A Marsh; A B Spurdle; B C Turner; S Fereday; H Thorne; G M Pupo; G J Mann; J L Hopper; J F Sambrook; G Chenevix-Trench
Journal:  Breast Cancer Res       Date:  2001-07-17       Impact factor: 6.466

5.  Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.

Authors:  S Wang-Gohrke; W Weikel; H Risch; D Vesprini; J Abrahamson; C Lerman; A Godwin; R Moslehi; O Olipade; J S Brunet; E Stickeler; D G Kieback; R Kreienberg; B Weber; S A Narod; I B Runnebaum
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

6.  Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families.

Authors:  Xuan Liu; Hans-Peter Sinn; Hans Ulrich Ulmer; Rodney J Scott; Ute Hamann
Journal:  Hered Cancer Clin Pract       Date:  2004-07-15       Impact factor: 2.857

7.  In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.

Authors:  Olga Kim; Eun Young Park; David L Klinkebiel; Svetlana D Pack; Yong-Hyun Shin; Zied Abdullaev; Robert E Emerson; Donna M Coffey; Sun Young Kwon; Chad J Creighton; Sanghoon Kwon; Edmund C Chang; Theodore Chiang; Alexander N Yatsenko; Jeremy Chien; Dong-Joo Cheon; Yang Yang-Hartwich; Harikrishna Nakshatri; Kenneth P Nephew; Richard R Behringer; Facundo M Fernández; Chi-Heum Cho; Barbara Vanderhyden; Ronny Drapkin; Robert C Bast; Kathy D Miller; Adam R Karpf; Jaeyeon Kim
Journal:  PLoS Genet       Date:  2020-06-04       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.